Title: Sorrento Therapeutics COVID-19 Pipeline Update, R&D Discussion and Management Q&A. Sorrento Therapeutics - We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19

For more information, visit www.sorrentotherapeutics.com. Sorrento will take over the execution of the phase 1 study from Personalized Stem Cells. ZTlido® was approved by the FDA on February 28, 2018. Is Sorrento Therapeutics a Ticking Time Bomb for Investors? Sorrento Therapeutics Adds Another COVID-19 Treatment to Its Pipeline The company's pipeline is large. RTX has completed a phase 1B trial for intractable pain associated with cancer and a phase 1B trial in osteoarthritis patients.

RTX has completed a phase 1B trial for intractable pain associated with cancer and a phase 1B trial in osteoarthritis patients. Forward-looking statements include statements regarding Sorrento’s pipeline and plans with respect to its strategic outlook and clinical and pre-clinical COVID-19 programs, its COVID-19 therapeutic and diagnostic product candidates and pipeline, and its proprietary technology platforms. Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.

Forward-looking statements include statements regarding Sorrento's pipeline and plans with respect to its strategic outlook and clinical and pre-clinical COVID-19 programs, its COVID-19 therapeutic and diagnostic product candidates and pipeline, and its proprietary technology platforms. The biotech licensed an adipose-derived mesenchymal stem cell (MSC) treatment from Personalized Stem Cells for patients with acute respiratory distress syndrome associated with COVID-19. Sorrento Therapeutics (NASDAQ:SRNE) has added another arrow to its COVID-19 quiver. For registered analysts and pre-certified participants: For other participants (webcast, with ability to submit questions during the session): https://edge.media-server.com/mmc/p/tun863t9, Management participants will include:Dr. Henry Ji, Chairman and CEODr. SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today released details about its upcoming COVID-19 Pipeline …

The MSC treatment was derived from fat cells, but the cells have the ability to turn into other types of tissue.
Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies ("G-MAB™ library"), clinical stage immuno-cellular therapies ("CAR-T", "DAR-T"), antibody-drug conjugates ("ADCs"), and clinical stage oncolytic virus ("Seprehvir®", “Seprehvec™”). The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today released details about its upcoming COVID-19 Pipeline Update call and webcast on October 13 th, 2020.. Sorrento Announces That Intranasal Administration of COVI-AMG™ Neutrali.. Chairman, President & Chief Executive Officer, VP-Pharmacovigilance & Clinical Operations, STI-2099 (encoded plasmid DNA expressing STI-2020), Neutralizing antibody cocktail (COVI-SHIELD™), STI-4398 (COVIDTRAP™: ACE2 receptor decoy protein), STI-3333 (T-VIVA-19™: protein-based vaccine), COVI-TRACE™: HP-LAMP Molecular Detection Test. This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc., under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. The Food and Drug Administration (FDA) authorized the start of a 20-patient phase 1 clinical trial in July, but the study hasn't started recruiting patients, according to ClinicalTrials.gov. Alexis Nahama, SVP of Corporate Development, • Therapeutic Pipeline – Clinical Stage (Management), • Therapeutic Pipeline – IND enabling Stage (Management).

Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVIDTRAP™, ACE-MAB™, COVI-MAB™, COVI-GUARD™, COVI-SHIELD™, COVI-AMG™ and T-VIVA-19™; and diagnostic test solutions, including COVI-TRACK™, COVI-STIX™ and COVI-TRACE™.
© 2020 Sorrento Therapeutics, Inc. All Rights Reserved. ContactAlexis Nahama, DVM (SVP Corporate Development)Email: mediarelations@sorrentotherapeutics.com. See you at the top!

Cumulative Growth of a $10,000 Investment in Stock Advisor, Sorrento Therapeutics Adds Another COVID-19 Treatment to Its Pipeline @themotleyfool #stocks $SRNE, These 2 Robinhood Favorites Could Double by 2022, 2 Coronavirus Stocks That Will Falter in a Market Crash. Salicyn-30 is a direct-acting antiviral designed to inhibit the reproduction of the novel coronavirus that causes COVID-19. The webcast will be available on the Sorrento Therapeutics’ website for 30 days at www.sorrentotherapeutics.com.

About Sorrento Therapeutics, Inc.Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers and COVID-19. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.

Conference ID: 2066037. Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers and COVID-19. Mike Royal, Chief Medical OfficerDr. Abivertinib was developed as a cancer treatment, but Sorrento hopes it could also help patients with COVID-19 by dampening the overactive immune system, which can cause problems in patients with COVID-19. Forward-Looking StatementsThis press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc., under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. SAN DIEGO - Sorrento Therapeutics, Inc. (Nasdaq: SRNE, 'Sorrento') today released details about its upcoming COVID-19 Pipeline Update call and webcast on October 13th, 2020. "The data suggests stem cells have the ability to reduce inflammation, reduce scar tissue formation, and to aid in clearing the lungs of fluid," Robert Harman, CEO of Personalized Stem Cells, noted in May. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies ('G-MAB library'), clinical stage immuno-cellular therapies ('CAR-T', 'DAR-T'), antibody-drug conjugates ('ADCs'), and clinical stage oncolytic virus ('Seprehvir', 'Seprehvec'). Sorrento Therapeutics COVID-19 Pipeline Update, R&D Discussion and Management Q&A Conference ID: 2066037 Date of call: 10/13/2020 Time of call: 16:30 Eastern Time Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks related to Sorrento’s and its subsidiaries’, affiliates’ and partners’ technologies and prospects and collaborations, including, but not limited to clinical development risks, including risks in the progress, timing, cost, and results of clinical trials and product development programs; risk of difficulties or delays in obtaining regulatory approvals; risks that clinical study results may not meet any or all endpoints of a clinical study and that any data generated from such studies may not support a regulatory submission or approval; risks that prior test, study and trial results may not be replicated in future studies and trials; risks of manufacturing and supplying drug product; risks related to leveraging the expertise of its employees, subsidiaries, affiliates and partners to assist the company in the execution of its therapeutic and diagnostic product candidates’ strategies; risks related to the global impact of COVID-19; and other risks that are described in Sorrento’s most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento’s Annual Report on Form 10-K for the year ended December 31, 2019, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Title: Sorrento Therapeutics COVID-19 Pipeline Update, R&D Discussion and Management Q&A, Expected Duration: 60 minutes + questions (analysts and general public), For registered analysts and pre-certified participants, For other participants (webcast, with ability to submit questions during the session): https://edge.media-server.com/mmc/p/tun863t9, Management participants will include: Dr. Henry Ji, Chairman and CEO, Dr. Mark Brunswick, SVP and Head of Regulatory and Quality, Dr. Robert Allen, SVP, Antiviral and Oncolytic Immunotherapy Development, Dr. Alexis Nahama, SVP of Corporate Development, R&D Day Agenda: Strategic Outlook (Dr. Henry Ji), Therapeutic Pipeline - Clinical Stage (Management), Therapeutic Pipeline - IND enabling Stage (Management), STI-2099 (encoded plasmid DNA expressing STI-2020), Neutralizing antibody cocktail (COVI-SHIELD), STI-4398 (COVIDTRAP: ACE2 receptor decoy protein), STI-3333 (T-VIVA-19: protein-based vaccine), COVI-TRACE: HP-LAMP Molecular Detection Test.

Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks related to Sorrento's and its subsidiaries', affiliates' and partners' technologies and prospects and collaborations, including, but not limited to clinical development risks, including risks in the progress, timing, cost, and results of clinical trials and product development programs; risk of difficulties or delays in obtaining regulatory approvals; risks that clinical study results may not meet any or all endpoints of a clinical study and that any data generated from such studies may not support a regulatory submission or approval; risks that prior test, study and trial results may not be replicated in future studies and trials; risks of manufacturing and supplying drug product; risks related to leveraging the expertise of its employees, subsidiaries, affiliates and partners to assist the company in the execution of its therapeutic and diagnostic product candidates' strategies; risks related to the global impact of COVID-19 and other risks that are described in Sorrento's most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento's Annual Report on Form 10-K for the year ended December 31, 2019, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Mark Brunswick, SVP and Head of Regulatory and QualityDr.

Fx Verminator Mk2, What Everyday Things Are Sins, What Was A Major Difference Between Charles X And Louis Philippe?, Why I Want To Be A Hairdresser Essay, Did Tatsuma Suguro Die, Iris Dark Model, Gold Rate In Pakistan 24k Per Tola, Nitecore Nm01 Battery Replacement, Ice Pigeon Facts, Andrea Riseborough Eyes, Oscar Pistorius Movie Netflix, Sins Of The Father Puzzle Solver, Chuck Australian Slang, Metal Lathe Cutting Speed Chart Metric, Showering After Pooping Without Wiping, Harry Caray Spouse, Eufy Doorbell Theft Protection, Imposters Season 3 Cast, Alexander Kostylev Net Worth, Scintillating Scotoma Anxiety, Is Blueface Mexican, How Individuals Perceive Themselves And Are Perceived By Others Essay, Thesis Statement For Mardi Gras, Winnie Hollman Biography, Csgo Map Commands, Aba Research Proposal, Reaction Paper About The Secret Life Of Walter Mitty, Birthday Fart Puns, Usda Egg Plant Numbers, Tallest Mlb Player 2020, Grant Shaffer Pineapple, Braydon Price Truck For Sale, Whirlpool Ice Dispenser Flap Not Closing, Alexa Power Outage Notification, Liliana Gandolfini 2020, Physical Education 3 Crossword Tennis Answer Key, Undead Warrior Name Generator, Maisie Mae Roffey Age, Albion Online Best Resource To Gather 2020,